Enzon may concentrate on novel drugs

A move by Enzon to spin off its biotech business has triggered interest in finding a buyer for its specialty pharmacy business instead. And that could leave the company devoted to developing new therapeutics. Enzon issued a release saying it could sell off its entire specialty pharmacy business or would consider selling off individual products: Oncaspar, DepoCyt, Abelcet and Adagen, as well as its Indianapolis, IN manufacturing facility. 

"During our efforts to spin-off our biotechnology business, it became clear that we should also explore attractive opportunities for Enzon's other businesses," said CEO Jeffrey H. Buchalter. "Our decision to explore alternatives for our specialty pharmaceuticals business is an outgrowth of that thinking and has the potential to allow Enzon to focus exclusively on our novel biotechnology business as an alternative to our previously announced spin-off."

- check out Enzon's release

Suggested Articles

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.

A phase 1/2b test showed Roche's antibody mosunetuzumab can trigger durable responses in a significant minority of hard-to-treat NHL patients.